|
Dr.
Dinesh Patel,
Managing Director, vSpring
Capital
Dr.
Patel is a Managing Director and Founding Partner of vSpring
Capital, an early stage venture capital fund with $125 million
under management. The firm is currently fundraising for vSpring
Fund II ($150 million target).
Dr. Patel is also the Founder, Chairman, President & CEO of
Ashni Naturaceuticals, Inc. a company that specializes in the
research, development and marketing of clinically tested and
patent-protected naturaceutical products. In 1999, Dr Patel
Co-founded and was the Chairman of Salus Therapeutics, Inc., a
biotechnology company focused on the research and development of
nucleic acid-based therapeutics, including antisense and gene
therapy drugs. In August 2003 publicly traded Genta, Inc
acquired Salus for $30 million. From 1985 - 1999, Dr. Patel
served as Co-founder, Chairman of The Board of Directors,
President & CEO, of TheraTech, Inc., a Salt Lake City, Utah
based company, that has been a pioneer in the development and
manufacture of innovative drug delivery products. Under Dr.
Patel's guidance, TheraTech established strategic alliances with
major pharmaceutical companies including Eli Lilly, Pfizer,
Proctor & Gamble, Roche, and SmithKline Beecham. TheraTech
went public in 1992 and became profitable in 1997. In January
1999, TheraTech was acquired for approximately $350 million by
Watson Pharmaceuticals, a California based company
Dr. Patel has been the recipient of numerous awards, including
US Small Business Administration's Business Achiever Award, and
Scientific and Technology Award (State of Utah), and
Entrepreneur of the Year Award (Mountain West Venture Group), to
name just a few.
Born and raised in Zambia,
Africa Dr Patel got his undergraduate degree from India and
his doctorate degree from University of Michigan. Dr Patel and
his wife, Kalpana and children, Ashish and Avni reside in Salt
Lake City, Utah. Dr Patel is active in the Indian and local
community serving on several boards and as an active donor for
various charitable causes.
|